AORT ARTIVION, INC.
FY2025 10-K
ARTIVION, INC. (AORT) filed its fiscal year 2025 10-K annual report with the SEC on Feb 18, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Manufacturer and distributor of medical devices and implantable human tissues for cardiac and vascular surgery, focusing on aortic disease treatment
- • New product launch: Arcevo™ LSA Hybrid Stent Graft System introduced in EMEA and APAC in 2025, with US PMA trial ongoing, plus PerClot® hemostatic powder manufacturing started Q2 2023
Management Discussion & Analysis
- • Revenue $441.3M in 2025, up 14% YoY from $388.5M in 2024; constant currency increase 13%
- • Gross margin 64% in 2025, flat YoY despite 14% gross margin dollar growth to $284.2M
Risk Factors
- • Regulatory risk: Italian medical device overpayment repayment exposure $2.3M for 2019–2025 period under Ministerial Decree, potential further government assessment
- • Geopolitical risk: NEXUS products solely made in Israel amid Middle East conflicts, risking supply disruption from war, sanctions, or export controls
Financial SummaryXBRL
Revenue
$441M
Net Income
$10M
Gross Margin
64.4%
Operating Margin
7.6%
Net Margin
2.2%
ROE
2.2%
Total Assets
$885M
EPS (Diluted)
$0.21
Operating Cash Flow
$40M
Source: XBRL data from ARTIVION, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on ARTIVION, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.